cover image Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2024 About Prime Therapeutics Prime Therapeutics...

High discontinuation rates highlight the importance of patient support programs to maximize the value of GLP-1 therapies

Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s

Update by Eagan-based Prime Therapeutics finds more patients quitting the popular weight-loss medications because of cost, access or short-term success